Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management.
Bilal H, Khan MN, Khan S, Fang W, Chang W, Yin B, Song NJ, Liu Z, Zhang D, Yao F, Wang X, Wang Q, Cai L, Hou B, Wang J, Mao C, Liu L, Zeng Y.
Bilal H, et al. Among authors: khan mn.
Mycology. 2023 Oct 20;15(1):30-44. doi: 10.1080/21501203.2023.2265664. eCollection 2024.
Mycology. 2023.
PMID: 38558839
Free PMC article.
Review.
Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors. Prospective studies and long-term surveillance are required to explore the impact of specific inhibitors on the incidence and severity of candid …
Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors. Prospective …